Literature DB >> 3104180

[Interval therapy in effective treatment of angina pectoris using nitroglycerin patch systems. A controlled study with determination of nitroglycerin plasma levels].

G Reiniger, G Menke, A Boertz, F Kraus, W Rudolph.   

Abstract

In ten patients with angiographically-documented coronary artery disease, stable angina pectoris and reproducible exercise-induced ST-segment depression, the extent and duration of antiischemic and antianginal effects of transdermal nitroglycerin patches delivering 10 mg/24 hours were investigated according to a double-blind, crossover, placebo-controlled protocol. Exercise testing and blood sampling for determination of nitroglycerin plasma concentrations were carried out at 2.5 and twelve hours after initial application, at 2.5, twelve and 24 hours after renewed application subsequent to a twelve-hour treatment pause as well as at 2.5 hours after application of a third patch (Figure 1). At 2.5 hours after initial application there was a reduction in exercise-induced ST-segment depression from 2.7 mm +/- 0.19 (SEM) to 0.75 +/- 0.2 (-72%; p less than 0.001) (Figure 2). The exercise capacity to onset of 1 mm ST-segment depression increased from 117 Watt X min +/- 34 (SEM) to 361 Watt X min +/- 84 (+210%; p less than 0.001) (Figure 3). At twelve hours, exercise-induced ST-segment depression was reduced only from 2.5 mm +/- 13 to 1.77 +/- 0.2 (-32%; p less than 0.01) and the increase in exercise capacity to onset of 1 mm ST-segment depression was narrowed from 136 Watt X min +/- 28.5 to 215 Watt X min +/- 43 (+59%; p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3104180

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  8 in total

1.  The effect of transdermal nitroglycerin on exercise tolerance in relation to patch application time--a meta-analysis.

Authors:  T O Klemsdal; K Gjesdal
Journal:  Cardiovasc Drugs Ther       Date:  1992-12       Impact factor: 3.727

Review 2.  Intermittent or continuous transdermal nitroglycerin: still an issue, or is the case closed?

Authors:  T O Klemsdal; K Gjesdal
Journal:  Cardiovasc Drugs Ther       Date:  1996-03       Impact factor: 3.727

3.  Nitrate patches: duration of action and loss of efficacy. Reflections on the nitrates' mode of action.

Authors:  W D Bussmann
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 4.  Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.

Authors:  S Silber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 5.  Pharmacokinetic considerations in the use of newer transdermal formulations.

Authors:  G Ridout; G C Santus; R H Guy
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

Review 6.  Transdermal nitroglycerin (glyceryl trinitrate). A review of its pharmacology and therapeutic use.

Authors:  P A Todd; K L Goa; H D Langtry
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

7.  Transdermal nitrate therapy: bioavailability during exercise increases transiently after the daily change of patch.

Authors:  K Gjesdal; T O Klemsdal; E O Rykke; J E Bredesen
Journal:  Br J Clin Pharmacol       Date:  1991-05       Impact factor: 4.335

8.  Anti-ischemic effects of first and second dose of 20 mg isosorbide dinitrate administered 5 hours apart: attenuation of effects despite rising plasma concentration.

Authors:  G Lehmann; G Reiniger; H Wolf; A Beyerle; W Rudolph
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.